After Flops, Ironwood Rebuilds It Pipeline With Liver Disease Deal
Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) has advanced plans to build its pipeline after securing a chance to license Cour Pharmaceuticals’ liver disease candidate…
Ironwood Pharmaceuticals Q3 Adj. EPS $0.33 Beats $0.31 Estimate, Sales $103.75M Miss $105.40M Estimate
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.31 by 6.45 percent. This is a 43.48 percent increase over earnings of $0.23 per share
Earnings Scheduled For November 4, 2021
Companies Reporting Before The Bell
• DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
Morgan Stanley Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $14
Morgan Stanley analyst David Lebowitz maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Equal-Weight and raises the price target from $13 to $14.
Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS Label
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for LINZESS® (linaclotide) based on
The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 12)
Stocks That Hit 52-Week Highs On Thursday
Thursday's morning session saw 119 companies set new 52-week highs.
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 11)